SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-166938
Filing Date
2024-06-24
Accepted
2024-06-24 16:06:01
Documents
14
Period of Report
2024-06-19
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d860451d8k.htm   iXBRL 8-K 36683
2 EX-3.1 d860451dex31.htm EX-3.1 27056
  Complete submission text file 0001193125-24-166938.txt   199360

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA antx-20240619.xsd EX-101.SCH 2874
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20240619_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20240619_pre.xml EX-101.PRE 11723
17 EXTRACTED XBRL INSTANCE DOCUMENT d860451d8k_htm.xml XML 3759
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 241064290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)